Item request has been placed!
×
Item request cannot be made.
×
Processing Request
[COX and study of cancer therapy].
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Yamada N;Yamada N; Ohira M; Hirakawa K
- Source:
Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2004 Aug; Vol. 31 (8), pp. 1147-51.
- Publication Type:
English Abstract; Journal Article; Review
- Language:
Japanese
- Additional Information
- Source:
Publisher: Gan To Kagaku Ryohosha Country of Publication: Japan NLM ID: 7810034 Publication Model: Print Cited Medium: Print ISSN: 0385-0684 (Print) Linking ISSN: 03850684 NLM ISO Abbreviation: Gan To Kagaku Ryoho Subsets: MEDLINE
- Publication Information:
Publication: Tokyo : Gan To Kagaku Ryohosha
Original Publication: Tōkyō, Gan to Kagaku Ryōhōsha [1974?]-
- Subject Terms:
- Abstract:
The increased expression of COX-2 in carcinoma tissue is found in gastric cancer, lung cancer and breast cancer as well as colon cancer. It was shown that COX-2 played an important role in carcinogenesis by an experiment using a cultured cell and an animal experiment using a knockout mouse. The inhibitory effect of COX-2 inhibitor on polyps in familial adenomatous polyposis (FAP) patients was reported from the clinical aspect, and the U. S. Food and Drug Administration (FDA) approved administration of a COX-2 inhibitor to FAP patients. COX-2 plays an important role in proliferation, invasion and metastasis of cancer. COX-2 expression was reportedly enhanced in lung cancer by an anticancer agent and radiotherapy, and clinical application of a COX-2 inhibitor is attempted. In addition, the experimental examination showed the inhibitory effect of a COX-2 inhibitor on hematogenous metastasis of colon cancer. The mechanism of the COX-2 inhibitor remains unclear. Clinical application of the COX-2 inhibitor to an effective anti-tumor agent is expected after more studies have been conducted on its molecular biologic function.
- Number of References:
27
- Accession Number:
0 (Anti-Inflammatory Agents, Non-Steroidal)
0 (Cyclooxygenase 2 Inhibitors)
0 (Cyclooxygenase Inhibitors)
0 (Isoenzymes)
0 (Membrane Proteins)
EC 1.14.99.1 (Cyclooxygenase 2)
EC 1.14.99.1 (PTGS2 protein, human)
EC 1.14.99.1 (Prostaglandin-Endoperoxide Synthases)
- Publication Date:
Date Created: 20040831 Date Completed: 20040903 Latest Revision: 20081121
- Publication Date:
20231215
- Accession Number:
15332534
No Comments.